Financial Data and Key Metrics Changes - Fourth quarter revenue was $43.6 million, an increase of $5.3 million, or 14%, compared to Q4 2024 [20] - Full year total revenue was $147.2 million, up 17% from 2024, with screening revenue of $138.6 million, up 28% [20][21] - Net loss for Q4 2025 was $99.2 million, a 2% increase compared to Q4 2024, while full year net loss improved by 80% to $408.4 million [22] - Non-GAAP adjusted gross profit for Q4 2025 was $23.1 million, a 29% increase compared to Q4 2024 [23] - Adjusted EBITDA for Q4 2025 was -$71.8 million, an improvement of 15% compared to Q4 2024 [24] Business Line Data and Key Metrics Changes - U.S. Galleri tests volume grew 36% to over 185,000 tests in 2025, with revenue growth of 26% [8] - Development services revenue decreased by 49% to $8.6 million in 2025 [21] Market Data and Key Metrics Changes - The prescriber base for Galleri increased by 30% to approximately 17,000 providers [8] - The company is focused on expanding awareness of multi-cancer early detection and anticipates growing conviction in Galleri among patients, providers, and employers [9] Company Strategy and Development Direction - The company plans to expand its field sales and medical team to drive commercial momentum [7] - The PMA submission to the FDA for Galleri marks a critical step in making the test available to more people [9] - The company aims to leverage strong results from clinical trials to expand partnerships and access to Galleri [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for Galleri to bend the cancer mortality curve at a population scale [16] - The company reiterated guidance for Galleri sales growth of 22%-32% and cash burn for 2026 to be no more than $300 million [26] - The cash runway extends into 2030, positioning the company well for future growth [26] Other Important Information - The NHS-Galleri trial showed a fourfold increase in cancer detection rates and a significant reduction in stage 4 cancer diagnoses [5][12] - The company plans to present full data from the NHS-Galleri and PATHFINDER 2 studies in mid-2026 [27][90] Q&A Session Summary Question: Will the FDA approval decision be impacted by missing the stage shift endpoint? - Management confirmed that the FDA will focus on clinical performance and safety, and there is no obvious correlation between the NHS-Galleri study results and the FDA's view on the test [31] Question: How does the NHS-Galleri trial impact the strategy to expand Galleri internationally? - Management believes the strong data from the NHS-Galleri trial will be compelling for discussions with other countries [36] Question: What is the probability of FDA approval unchanged as a result of the NHS Galleri readout? - Management indicated that the probability remains unchanged, focusing on clinical performance and safety in their submission [45][50] Question: What are the next steps regarding the NHS and the multi-cancer early detection tests? - Management has ongoing conversations with the NHS and anticipates that they will want to see full results before engaging in meaningful discussions [62] Question: How will Medicare evaluate the NHS trial data for coverage? - Management believes they will provide a robust package of data to Medicare, including substantial stage 4 reduction and overall clinical performance [67]

Group 1 - The core viewpoint is that Precision Science expects to achieve profitability by 2026, with revenue forecasts of $3.227 billion, $3.613 billion, and $4.053 billion for 2025 to 2027, respectively, and a net profit improvement from a loss of $58 million in 2025 to a profit of $82 million in 2026 [1] - The company raised its full-year revenue guidance for 2025 to between $3.22 billion and $3.235 billion during the Q3 earnings call on November 3, 2025, with an adjusted EBITDA target of $470 million to $480 million [1] Group 2 - Abbott announced plans to acquire Exact Sciences, which could accelerate the company's international expansion [2] - The launch of the multi-cancer early detection test, Cancer Guard, in Q3 2025 will be a key factor for business growth based on its commercialization progress and market acceptance [2] Group 3 - The Cologuard product is driving an increase in screening numbers, with a year-on-year increase of 250,000 people in Q3 2025, supported by brand strength and execution efficiency [3] - The company is enhancing profit margins through laboratory optimization and supply chain management, with a focus on cost control and operational efficiency planned for 2026 [3]

Summary of GRAIL Analyst Day - November 13, 2025 Company Overview - **Company**: GRAIL (NasdaqGS:GRAL) - **Industry**: Multi-Cancer Early Detection (MCED) Testing Key Highlights 1. **Introduction and Purpose**: The Analyst Day aimed to share key business highlights and progress since GRAIL became a public company in June 2024, focusing on population-scale multi-cancer early detection [8][9][10] 2. **Financial Performance**: - Revenue for 2024 was $125 million, with a growth rate of 25% year-over-year for the first nine months of 2025 [12] - A $325 million PIPE financing was announced, providing capital for future growth [13] - Cash burn for the year was reduced to $290 million, with improved margins increasing to 55% from 41% the previous year [14] 3. **Operational Capacity**: GRAIL's lab can run up to 1 million tests, showcasing significant automation and efficiency improvements [12][15] Clinical and Research Insights 1. **Cancer Detection Landscape**: - Cancer is projected to become the leading cause of death globally, surpassing cardiovascular disease [16] - The current screening tests only detect about 14% of incident cancers, generating over 8 million false positives annually in the U.S. [23][24] 2. **Galleri Test Performance**: - The Galleri test has shown a positive predictive value (PPV) of 62% in the PATHFINDER II study, significantly higher than traditional single cancer screening methods [21][32] - The specificity of the Galleri test was reported at 99.6%, minimizing false positives [33] - Episode sensitivity for all cancers was 40.4%, with higher sensitivity for cancers responsible for two-thirds of U.S. cancer deaths at 74% [34] 3. **PATHFINDER II Study**: - Enrolled nearly 35,000 participants, making it the largest interventional MCED study in the U.S. [30] - The study demonstrated that the Galleri test could detect cancers earlier, with 69% of identified cancers being in early stages [36] - The study also showed a low rate of invasive procedures (0.6%) due to positive test results, indicating a favorable safety profile [37] Future Directions 1. **FDA Submission**: GRAIL plans to submit data from the PATHFINDER II study to the FDA by Q1 2026, aiming for Galleri to be the first FDA-approved MCED test [26][27] 2. **NHS-Galleri Study**: A large-scale study in the UK involving 140,000 participants is underway to assess the utility of the Galleri test in a screening population [42][43] 3. **Reimbursement Pathways**: Discussions on alternative reimbursement strategies, including potential use as a surveillance tool for high-risk populations, are ongoing [66] Additional Insights - The importance of building a robust evidence base for the Galleri test was emphasized, with a focus on clinical validation and performance rather than mortality outcomes [57][58] - The potential for Galleri to complement existing single cancer screening tests was highlighted, aiming to improve overall cancer detection rates and reduce healthcare costs associated with false positives [24][25] This summary encapsulates the critical points discussed during the GRAIL Analyst Day, focusing on the company's advancements in cancer detection technology and its strategic direction moving forward.